Clinical Data from OUS Studies Get Guidance From FDA
Today the FDA released a draft guidance that could give manufacturers more direction on how they can use clinical data from studies conducted outside of the United States to support device submissions.
It is worth noting that this is not a new FDA policy. The agency is simply proving more insight on the issue.
Once final, the guidance will offer the following:
- FDA’s policy of accepting scientifically valid clinical data from foreign clinical studies in support of premarket submissions for medical devices
- The special considerations that apply when using OUS data, including applicability of the data to intended patient populations within the United States and study design issues,
- Recommendations to assist sponsors in developing data that meet FDA standards to support approval of clearance of the device in the U.S.
The comment period for the draft, Acceptance of Medical Device Clinical Data from Studies Conducted Outside the United States (OUS), is open for the next 90 days.
Related Stories
FDA’s New Program Puts Life-Saving Technologies on Fast Track to Approval
Related Articles
-
The final guidance includes recommendations for various elements of animal studies, including the credentials for personnel conducting an animal study, and the study planning and conduct process, including selecting an appropriate animal model, study monitoring, and study evaluation.
-
The draft guidance covers DCT design, informed consent, the use of remote clinical trial visits, safety monitoring and software used in conducting DCTs for drugs, biological products, and devices. The comment period is open until August 1, 2023.
-
The guidance seeks to balance the need to obtain data on the safety and effectiveness of drugs, biological products and medical devices in the pediatric population with risks associated with exposure to such products and the reality that children cannot…
-
The two new final guidances are intended to increase transparency to stakeholders on the FDA’s approach to the issuance and tracking of 522 orders and post-approval study requirements.
